Vaccine immunotherapy
A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
1. A composition for use in eliciting an immune response in a patient, the composition comprising:
(a) a primary cell-derived biologic including IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and
(b) a vaccine comprising a viral vector encoding at least one antigen, wherein the viral vector is a retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, or poxvirus.
2. The composition of claim 1 , wherein the viral vector is a poxvirus and wherein the poxvirus is a vaccinia, modified vaccinia Ankara (MA), NYVAC, avipox, TROVAX, fowlpox, or canarypox.
3. The composition of claim 2 , wherein the poxvirus is a canarypox.
4. The composition of claim 3 , wherein the canarypox is ALVAC or ALVAC(2).
5. The composition of claim 1 , wherein the at least one antigen is at least one tumor associated antigen.
6. The composition of claim 1 , further comprising one or more co-stimulatory molecules.
7. The composition of claim 6 , wherein the one or more co-stimulatory molecules is selected from the group consisting of abatacept, belatacept, CD28-SuperMAB, a B7/CD28 co-stimulatory molecule, a TNF superfamily co-stimulatory molecule, and a SLAM family co-stimulatory molecule.
8. The composition of claim 1 , wherein the viral vector further encodes LFA-1, ICAM-1, and B7.1, or combination thereof.
9. The composition of claim 8 , wherein the viral vector encodes LFA-1, ICAM-1, and B7.1.
10. The composition of claim 1 , wherein the viral vector encodes one or more proteins which lead to over-expression of co-stimulatory proteins in the patient.
11. A method of vaccination, the method comprising:
administering a composition comprising a primary cell-derived biologic including IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ to a patient; and
administering a vaccine comprising a viral vector encoding at least one antigen to the patient, wherein the viral vector is a retrovirus, adenovirus, adeno-associated virus (AAV), herpes virus, or poxvirus.
12. The method of claim 11 , wherein the viral vector is a poxvirus and wherein the poxvirus is a vaccinia, modified vaccinia Ankara (MA), NYVAC, avipox, TROVAX, fowlpox, or canarypox.
13. The method of claim 12 , wherein the poxvirus is a canarypox.
14. The method of claim 13 , wherein the canarypox is ALVAC or ALVAC(2).
15. The method of claim 11 , wherein the method further comprises administering abatacept, belatacept, CD28-SuperMAB, a B7.CD28 co-stimulatory molecule, a TNF superfamily co-stimulatory molecule, a SLAM family co-stimulatory molecule, or combinations thereof.
16. The method of claim 11 , wherein the method further comprises administering an anti-CTLA-4 antibody.
17. The method of claim 11 , wherein the viral vector further encodes LFA-1, ICAM-1, B7.1, or combination thereof.
18. The method of claim 11 , wherein the viral vector further encodes LFA-1, ICAM-1, and B7.1.
19. The method of claim 11 , wherein the viral vector further encodes one or more proteins which lead to over-expression of co-stimulatory proteins in the patient.